![]() 006280 6 months ago | Other | ₩1,500 Per Share |
![]() 006280 27 Dec 2023 | Other | ₩1,500 Per Share |
![]() 006280 28 Dec 2022 | Other | ₩1,750 Per Share |
![]() 006280 29 Dec 2021 | Other | ₩2,000 Per Share |
![]() 006280 29 Dec 2020 | Other | ₩1,500 Per Share |
5 Aug 2025 (In 4 weeks) Date | | 272.49 Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
18 Mar 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
![]() 006280 6 months ago | Other | ₩1,500 Per Share |
![]() 006280 27 Dec 2023 | Other | ₩1,500 Per Share |
![]() 006280 28 Dec 2022 | Other | ₩1,750 Per Share |
![]() 006280 29 Dec 2021 | Other | ₩2,000 Per Share |
![]() 006280 29 Dec 2020 | Other | ₩1,500 Per Share |
5 Aug 2025 (In 4 weeks) Date | | 272.49 Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
18 Mar 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Il-Sup Huh Ph.D. CEO | KRX SM Exchange | KR7006280002 ISIN |
KR Country | - Employees | 27 Dec 2012 Last Dividend | 7 Jun 2013 Last Split | - IPO Date |
GC Biopharma Corp. is a prominent biopharmaceutical entity engaged in the innovation, development, and international distribution of pharmaceutical medicine. Founded in 1967 and headquartered in Yongin-Si, South Korea, the company has etched a global footprint, including a vast array of over-the-counter medications, treatments for various diseases, and vaccines. As a subsidiary of Green Cross Holdings Corporation, it has consolidated its reputation by offering a comprehensive suite of therapeutic solutions, underscoring its commitment to improving healthcare standards worldwide.
Acustop Cataplasma: An over-the-counter offering designed for analgesic and anti-inflammatory purposes, providing relief from pain and inflammation.
Kenhancer plaster: Targeted for anti-inflammatory effects, this product helps in reducing inflammation.
Zenol Cool Type and Zenol Mild Hot Type: Drugs formulated for anti-inflammatory purposes and pain relief, catering to varying patient preferences and conditions.
Albumin-GCC injection (inj.): Administered for conditions like hypoalbuminemia and shock due to acute hemorrhage, as well as in cases of low albumin synthesis.
Antithrombin-III (AT-III) inj.: Used in the treatment of hereditary antithrombin-III deficiency, a critical condition affecting the blood's ability to clot.
Facnyne inj.: A specialized formula for addressing hemophilia B, aiding in the management of this genetic bleeding disorder.
Fibrinogen: Offered for the treatment of hypofibrinogenemia and afibrinogenemia, focusing on conditions where fibrinogen levels in the blood are low.
Gamma Globulin: Essential for addressing hypogammaglobulinemia and agammaglobulinemia, diseases marked by an abnormally low presence of antibodies.
GCFLU Quadrivalent and GC FLU pre-filled syringe inj.: Vaccines formulated for the prevention of influenza, highlighting the company's role in infectious disease control.
GreenGene F inj.: A hemostatic agent for persons with hemophilia A, aimed at controlling bleeding symptoms.
GreenGene inj.: Another product for hemophilia A, focusing on treating bleeding episodes induced by the condition.
Greenplast Q: Designed for sealing tissues and closing wounds, facilitating the body's natural healing process.
Green-VIII inj.: Provides Hemophilia A patients with blood coagulation factor VIII, critical for blood clotting.
Hepabig inj.: Administered for hepatitis B, a liver infection caused by the hepatitis B virus (HBV).
Histobulin: Used in treating bronchial asthma, offering relief from chronic inflammatory disease of the airways.
Hunterase: A treatment for Hunter syndrome, a rare genetic disorder that affects the body's ability to break down certain sugars.
I.V. Hepabig inj.: Aimed at preventing the recurrence of hepatitis B in patients following liver transplantation.
I.V.-Globulin SN inj. 5%: Provides immune system support, crucial for fighting off infections.
Immuncell-LC: A treatment designed to address liver cancer, showcasing the company's commitment to oncological healthcare solutions.
Sero-Tet inj.: Used for the prophylaxis of tetanus and the reduction of tetanus symptoms, further emphasizing GC Biopharma's role in preventive healthcare.
Shinbaro: An agent for anti-inflammation and pain relief, specifically targeting osteoarthritis, a common form of arthritis.
Varicella Vaccine-GCC inj.: A vaccine for the prophylaxis of varicella, also known as chickenpox, a highly contagious viral infection.
Varicella-Zoster Immune Globulin-GCC inj.: Offers passive immunity to susceptible immunodeficient children exposed to varicella, preventing the development of the disease.